Pfizer launches early safety trial for potential kidney disease treatment
NCT ID NCT06994897
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This early-stage study tests a new medicine, PF-07985631, in healthy adults to see if it is safe and how the body handles it. The medicine is being developed for a kidney disease called IgA nephropathy. Participants receive either the drug or a placebo as an injection or IV, and most get just one dose. The study lasts about 4 to 6 months and involves blood tests and safety checks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer Clinical Research Unit - Brussels
RECRUITINGBrussels, Bruxelles-capitale, Région de, B-1070, Belgium
Conditions
Explore the condition pages connected to this study.